Nektar Therapeutics Falls 8.3% (NKTR)

Shares of Nektar Therapeutics NKTR are currently down 8.3% at $12.90 per share during Monday afternoon trading. Today's trading range for shares of Nektar Therapeutics has been between $12.74 and $13.45 per share. The consensus price target of analysts covering the company's stock is $16.88 per share. Volume of 3.4 million shares is more than 6 times the daily average volume of 540,000 shares. Nektar Therapeutics NKTR is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for leading biopharmaceutical company partners. Read more from Benzinga's Company news.